Cullinan Therapeutics
CGEMPhase 2Cullinan Therapeutics is a public, clinical-stage biotech company driving forward a deliberate pipeline of innovative therapies in autoimmune diseases and oncology. The company's strategy centers on rigorous scientific decision-making and strategic risk-taking to accelerate promising molecules. Key near-term catalysts include initial clinical data for CLN-978 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in Q2 2025, and the completion of a rolling NDA submission for zipalertinib in EGFR exon 20 insertion non-small cell lung cancer (NSCLC).
CGEM · Stock Price
Historical price data
AI Company Overview
Cullinan Therapeutics is a public, clinical-stage biotech company driving forward a deliberate pipeline of innovative therapies in autoimmune diseases and oncology. The company's strategy centers on rigorous scientific decision-making and strategic risk-taking to accelerate promising molecules. Key near-term catalysts include initial clinical data for CLN-978 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in Q2 2025, and the completion of a rolling NDA submission for zipalertinib in EGFR exon 20 insertion non-small cell lung cancer (NSCLC).
Technology Platform
The company leverages deep expertise in immune modulation to develop novel therapeutic modalities, including T cell engagers and targeted small molecules, for autoimmune diseases and oncology.
Pipeline Snapshot
1010 drugs in pipeline
| Drug | Indication | Stage |
|---|---|---|
| CLN-081 | Non Small Cell Lung Cancer | Phase 1/2 |
| VK-2019 | Nasopharyngeal Carcinoma | Phase 1/2 |
| CLN-619 | Multiple Myeloma | Phase 1 |
| CLN-049 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 |
| CLN-978 | Rheumatoid Arthritis (RA | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Faces competition from established biologics and JAK inhibitors in autoimmunity, and from other approved EGFR exon 20 inhibitors (amivantamab, mobocertinib) in NSCLC. Differentiation hinges on demonstrating superior efficacy, safety, or novel mechanisms of action.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile